Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18875024 | 1.00 | GAA (0.50) | GAAMAPTPOLBKMT2AL3MBTL1 | |
| SCHEMBL11537780 | 0.91 | GAA (0.57) | GAAMAPTPOLBKMT2AL3MBTL1 | |
| SCHEMBL18875025 | 0.90 | KMT2A (0.48) | GAAMAPTPOLBKMT2AL3MBTL1 | |
| SCHEMBL18877712 | 0.86 | KMT2A (0.40) | GAAMAPTPOLBKMT2AL3MBTL1 | |
| SCHEMBL15746104 | 0.79 | MEN1 (0.46) | GAAMAPTPOLBKMT2AALDH1A1 | |
| SCHEMBL1218751 | 0.75 | POLB (0.60) | GAAMAPTPOLBL3MBTL1ALDH1A1 | |
| SCHEMBL10903734 | 0.74 | TSHR (0.62) | GAAMAPTPOLBKMT2AL3MBTL1 | |
| SCHEMBL13560875 | 0.73 | GAA (0.65) | GAAMAPTPOLBKMT2AALDH1A1 | |
| SCHEMBL13265283 | 0.73 | LMNA (0.59) | GAAMAPTPOLBKMT2AALDH1A1 | |
| SCHEMBL13624487 | 0.73 | POLB (0.53) | GAAMAPTPOLBKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10007164-B2 | Organic compounds, light modulating composition and light modulating devices employing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-06-26 | — | — | US | disclosed |
| US-20170146881-A1 | ORGANIC COMPOUNDS, LIGHT MODULATING COMPOSITION AND LIGHT MODULATING DEVICES EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10007164-B2 | Organic compounds, light modulating composition and light modulating devices employing the same | CRY1, XDH, CHRM1 | GAA 3660/4885MAPT 320/4885POLB 3602/4885 |
| US-20170146881-A1 | ORGANIC COMPOUNDS, LIGHT MODULATING COMPOSITION AND LIGHT MODULATING DEVICES EMPLOYING THE SAME | CRY1, XDH, CHRM1 | GAA 3660/4885MAPT 320/4885POLB 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.